IP Library Granted Patent US 6,974,571
Granted Patent B2
US 6,974,571 · App. 08/913,918 · Granted Dec 13, 2005

Isolated stromal cells and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,974,571
App. No.
08/913,918
Granted
Dec 13, 2005
Kind
B2
Abstract

Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells.

Claims (16)

1. An implantable container containing an isolated bone marrow stromal cell which comprises a first expressible gene construct encoding a protein, and a second expressible gene construct encoding a cytotoxic protein, which cytotoxic protein induces selective cell death in the presence of a drug specific for said cytotoxic protein, wherein said first and second expressible gene is under the control of a different promoter, further wherein the container physically isolates the stromal cell from immune cells of an animal when the container is implanted in the animal, and wherein the container has pores for permitting diffusion between the interior and the exterior of the container.

2. The container of claim 1 , wherein the first gene construct encodes a secreted protein.

3. The container of claim 1 , wherein the container is a microencapsulate stromal cell.

4. The container of claim 1 , wherein the container is a biocompatible matrix having the stromal cells incorporated therein.

5. The container of claim 1 , wherein the container comprises a membrane having pores which have a diameter not greater than about 0.3 micrometers.

6. The container of claim 5 , wherein the container comprises a membrane having pores which have a diameter not greater than about 0.25 micrometers.

7. The container of claim 5 , wherein the container comprises a membrane having pores which have a diameter not greater than about 0.1 micrometers.

8. The container of claim 1 , wherein the stromal cell comprises a third expressible gene construct encoding a protein.

9. The container of claim 8 , wherein the third expressible gene construct encodes an antibiotic resistance protein.

10. The container of claim 8 , wherein the first expressible gene construct and the third expressible gene construct are the same gene construct.

11. The container of claim 1 , wherein the stromal cell is a human stromal cell.

12. The container of claim 1 , wherein the stromal cell is obtained from bone marrow.

13. The container of claim 1 , containing at least 10 4 of the stromal cells.

14. The container of claim 1 , containing from 10 4 to 10 11 of the stromal cells.

15. A method of providing a protein to an animal, the method comprising implanting within the animal a container containing an isolated marrow stromal cell which comprises a first expressible gene construct encoding a protein, and a second expressible gene construct encoding a cytotoxic protein, which cytotoxic protein induces selective cell death in the presence of a drug specific for said cytotoxic protein, wherein said first and second expressible gene is under the control of a different promoter, further wherein the container physically isolates the stromal cell from immune cells of the animal, and wherein the container has pores for permitting diffusion between the interior and the exterior of the container.

16. The method of claim 15 , wherein said protein is a secreted protein.

Assignments (2)
LIEN Recorded Apr 30, 2009
From: ARTECEL, INC.; COGNATE BIOSERVICES, INC.; THERADIGM, INC.
To: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
Reel/Frame 022619/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 1997
From: PROCKOP, DARWIN J.; PEREIRA, RUTH F.; LEEPER, DENNIS B.; O'HARA, MICHAEL D.; KULKOSKY, JOSEPH; PHINNEY, DONALD; LAPTEV, ALEXY; CARO, JOSE
To: THOMAS JEFFERSON UNIVERSITY
Reel/Frame 008843/0562 →